Washington, April 8: A leading new tuberculosis vaccine, called MVA85A, has been found to be safe in its Phase I trial.
Lead researcher Dr. Helen McShane, reader in vaccinology and Wellcome senior fellow at the University of Oxford’s Jenner Institute in England, studied the effects of the vaccine specifically in people who had latent tuberculosis infection (LTBI), which can cause full-blown disease when re-activated.
For the study, the researchers recruited 12 individuals with LTBI, who did not have other complicating factors like HIV or hepatitis.